Baseline characteristics of analyzed patients
| Variables . | TDF (n = 39) . | LAM (n = 38) . | P . |
|---|---|---|---|
| Age, median (range), y | 59.5 (25-81) | 61 (21-83) | .64 |
| Sex | |||
| Male | 23 (59) | 21 (55.3) | .74 |
| Female | 16 (41) | 17 (44.7) | |
| Underlying hematological malignancy (DLBCL) | 39 (100) | 38 (100) | n.v. |
| Ann Arbor stage* | |||
| Stage III | 20 (51.3) | 18 (47.4) | .73 |
| Stage IV | 19 (48.7) | 20 (52.6) | |
| IPI score† | |||
| 1 | 2 (5.1) | 1 (2.6) | .57 |
| 2-3 | 15 (38.5) | 15 (39.5) | .92 |
| 4-5 | 22 (56.4) | 22 (57.9) | .89 |
| HBV status in the serum at pretreatment | |||
| HBsAg+ | 39 (100) | 38 (100) | n.v. |
| HBcAb+ | 32 (82.1) | 34 (89.5) | .35 |
| HBV DNA‡at pretreatment | |||
| HBV DNA+ | 12 (30.7) | 14 (36.8) | .57 |
| Median (range), IU/mL | 499 (100-948) | 483 (100-1800) | .58 |
| Transaminase level | |||
| AST ≤40 IU/L | 39 (100) | 38 (100) | n.v. |
| ALT ≤40 IU/L | 39 (100) | 38 (100) | n.v. |
| Scheduled induction immune-chemotherapy (R-CHOP-21) | 39 (100) | 38 (100) | n.v. |
| Variables . | TDF (n = 39) . | LAM (n = 38) . | P . |
|---|---|---|---|
| Age, median (range), y | 59.5 (25-81) | 61 (21-83) | .64 |
| Sex | |||
| Male | 23 (59) | 21 (55.3) | .74 |
| Female | 16 (41) | 17 (44.7) | |
| Underlying hematological malignancy (DLBCL) | 39 (100) | 38 (100) | n.v. |
| Ann Arbor stage* | |||
| Stage III | 20 (51.3) | 18 (47.4) | .73 |
| Stage IV | 19 (48.7) | 20 (52.6) | |
| IPI score† | |||
| 1 | 2 (5.1) | 1 (2.6) | .57 |
| 2-3 | 15 (38.5) | 15 (39.5) | .92 |
| 4-5 | 22 (56.4) | 22 (57.9) | .89 |
| HBV status in the serum at pretreatment | |||
| HBsAg+ | 39 (100) | 38 (100) | n.v. |
| HBcAb+ | 32 (82.1) | 34 (89.5) | .35 |
| HBV DNA‡at pretreatment | |||
| HBV DNA+ | 12 (30.7) | 14 (36.8) | .57 |
| Median (range), IU/mL | 499 (100-948) | 483 (100-1800) | .58 |
| Transaminase level | |||
| AST ≤40 IU/L | 39 (100) | 38 (100) | n.v. |
| ALT ≤40 IU/L | 39 (100) | 38 (100) | n.v. |
| Scheduled induction immune-chemotherapy (R-CHOP-21) | 39 (100) | 38 (100) | n.v. |
Unless otherwise indicated, data are n (%). No patient had hepatitis C or delta or HIV coinfections.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBcAb, hepatitis B core antibody; n.v., not valuable; TDF, tenofovir disoproxil fumarate.
Stage III is defined as multiple lymph node groups on both sides of the diaphragm; stage IV is defined as multiple extranodal sites or lymph nodes and extranodal disease.20
Five factors were included: age > 60 years, serum lactate dehydrogenase above normal, Eastern Cooperative Oncology Group performance status of 2 to 4, Ann Arbor stage III or IV, and extranodal involvement at >1 site. Each factor gets 1 point, and possible scores range from 0 to 5. A higher score indicates poorer prognosis.9
By real-time PCR (cutoff = 20 IU/mL).